ARHGEF10

Across TCGA pan-cancer cohorts, ARHGEF10 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ARHGEF10 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF10 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

HNSC, PAAD, and BRCA are the cancer types where ARHGEF10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.191	0.663	<.001	54	view →
PAAD	OS	Median	All	0.132	0.613	.002	15	view →
BRCA	OS	Median	All	0.638	0.963	.011	15	view →
STAD	OS	Median	IV	0.805	0.283	.031	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	III,IV	0.906	0.532	.041	6	view →
BLCA	OS	Median	All	0.114	0.446	.040	6	view →
COAD	OS	Median	III,IV	0.163	0.699	.002	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.939	0.724	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ARHGEF10–HNSC (OS)

Open the HNSC breakdown →